Fate Therapeutics Inc
(NAS:FATE)
$
3.68
0.23 (6.67%)
Market Cap: 418.90 Mil
Enterprise Value: 111.25 Mil
PE Ratio: 0
PB Ratio: 0.99
GF Score: 58/100 Fate Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023 / 09:00PM GMT
Release Date Price:
$5.55
(+2.59%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst
Perfect. Well, thank you, everyone, for joining us. I'm pleased to be joined by Scott Wolchko, President and CEO of Fate Therapeutics. Thank you so much.
J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, President & Director
Thank you. Thank you for having me.
Questions & Answers
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst
Yes, of course. 2023, a lot of changes for Fate, maybe we can start there, just talk us through what happened here? How much change has really come about for Fate on the back of this Janssen termination?
J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, President & Director
Sure. Obviously, the termination was sudden with respect to its developments. And it really caused us to obviously take a hard look at the strategic direction of the company, our assets, and we continued to favor the development and the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot